Publication | Closed Access

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Clinical TrialsTreatment OptionPharmacotherapyNeurologyMultiple SclerosisMedicineNeuroimmunologyNovel Therapy